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The Western diet has changed significantly over the last century, e.g. by an increased 
ratio of omega-6 (n-6) to n-3 polyunsaturated fatty acids (PUFA), particularly due to 
an increase in the use of vegetable oils like soy oil, rich in the n-6 PUFA linoleic acid 
(18:2n-6, LA), the precursor of arachidonic acid (20:4n-6, AA). Dietary fatty acids are 
incorporated into cell membranes of blood and tissues, where AA prevails as a result 
of the Western diet. AA and the long-chain (LC) n-3 PUFA eicosapentaenoic acid 
(20:5n-3, EPA), found in fatty fish and marine oils, compete as substrate for the 
synthesis of eicosanoids like e.g. prostaglandins by cyclooxygenase (COX) enzymes. 
AA-derived eicosanoids are generally more pro-inflammatory than their EPA-derived 
counterparts, and the former may be involved in both pathogenesis and exacerbation 
of chronic inflammatory diseases like inflammatory bowel disease (IBD) and 
rheumatic disorders.  
Both IBD and psoriatic arthritis (PsA) patients suffer joint pain, but in contrast 
to PsA patients, IBD-patients commonly have arthralgia, i.e. joint pain without 
arthritis. Nevertheless, arthralgia substantially reduces the health related quality of life 
(HRQOL) of patients. Both IBD and PsA patients need safe alternative or adjuvant 
treatment for joint pain, as COX-inhibitory drugs for joint pain have adverse effects, 
particularly in IBD-patients. Long-term oral administration of fish oil reduces the 
levels of nociceptive prostaglandin E2 (PGE2) and is considered a moderately effective 
and safe strategy for ameliorating joint pain. In a recent pilot study in IBD-patients, 10 
days administration of seal oil (SO), self-administrated as 10 mL × 3 daily by 
nasoduodenal feeding tube, reduced joint pain and IBD-disease activity. In the present 
thesis, eventual health benefits of administrating SO or whale oil (WO), 10 mL × 3 
daily, with focus on joint pain relief, in patients with IBD and PsA, were investigated 
in explorative pilot studies.       
 Duodenal administration of SO for 10 days normalised n-6 to n-3 PUFA and 
AA to EPA ratios in rectal mucosa of IBD-patients as compared with controls. In a 
8later similar study in IBD-patients, SO ameliorated joint pain and HRQOL, the former 
with prolonged effects, as compared with soy oil, which tended to exacerbate the 
condition. In another similar study, both SO and WO reduced joint pain and IBD-
disease activity and improved quality of life (QoL) in IBD-patients, with no significant 
group differences. The pain relief after SO and WO administration might in part be 
mediated by COX-inhibition as suggested by reduced PGE2 levels in plasma (tendency 
only with WO) as analysed by liquid chromatography tandem mass spectrometry. The 
application of experimental design enabled estimating the interaction PGE2/internal 
standard (IS) and selecting confidently an optimal amount of IS and a constant 
response factor in order to perform a reliable eicosanoid quantification.   
 In a rat model of IBD, short-term (seven days) pre-treatment with SO or cod 
liver oil (1 mL/day by gastric gavage) as supplement to a standard diet did not protect 
against subsequent dextran sulfate sodium (DSS) induced colitis, while soy oil 
aggravated the condition. In PsA patients, 14 days oral administration of SO reduced 
patients global assessment of disease four weeks post-treatment, but did not improve 
joint pain compared with soy oil. Twenty three % of PsA patients had elevated levels 
of faecal calprotectin suggesting asymptomatic, non-active colitis.   
 In conclusion, the present thesis suggests that short-term duodenal 
administration of blubber oils from marine mammals, like SO and WO, reduce joint 
pain and IBD-disease activity and improve QoL without significant adverse effects in 
IBD-patients with moderate disease activity, while short-term oral administration of 
SO does not improve joint or skin affections in PsA patients. 
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1. Background 
The Western diet has changed significantly over the last century, e.g. by an increased 
ratio of omega-6 (n-6) to n-3 polyunsaturated fatty acids (PUFA) [1]. This is 
particularly due to an increase in the use of vegetable oils like soy oil, rich in the n-6 
PUFA linoleic acid (18:2n-6, LA), the precursor of arachidonic acid (20:4n-6, AA). 
Dietary fatty acids (FA) are incorporated into cell membranes of blood and tissues, 
where AA prevails as a result of the Western diet [2]. AA and the long-chain (LC, i.e. 
20 carbons or more) n-3 PUFA eicosapentaenoic acid (20:5n-3, EPA), found in fatty 
fish and marine oils, compete as substrate for the synthesis of eicosanoids like e.g. 
prostaglandins by cyclooxygenase (COX) enzymes. AA-derived eicosanoids are 
generally more pro-inflammatory than their EPA-derived counterparts, and the former 
may be involved in both pathogenesis and exacerbation of chronic inflammatory 
diseases like inflammatory bowel disease (IBD) and rheumatic disorders [3, 4]. Both 
IBD and psoriatic arthritis (PsA) patients suffer joint pain, but in contrast to PsA 
patients, IBD-patients commonly have arthralgia, i.e. joint pain without arthritis [5]. 
Nevertheless, arthralgia substantially reduces the health related quality of life 
(HRQOL) of patients [6]. Both IBD and PsA patients need safe alternative or adjuvant 
treatment for joint pain, as COX-inhibitory drugs for joint pain have adverse effects, 
particularly in IBD-patients [7]. Long-term oral administration of fish oil reduces the 
levels of nociceptive prostaglandin E2 (PGE2) and is considered a moderately effective 
and safe treatment for joint pain [4]. Less information exists on the potential health 
benefits of blubber oils from marine mammals, like seal oil (SO) and particularly 
whale oil (WO).  
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2. Aims of the study 
2.1 Overall aim and context of thesis 
The Royal Ministry of Fisheries and Coastal Affairs (RMFCA), the central 
governmental administrator of marine mammals in Norway, has emphasised the need 
for utilizing meat and blubber from sea mammals like seal and whale [8]. The overall 
aim of the present thesis was to document eventual health benefits of administrating 
SO or WO, with focus on joint pain relief, in patients with IBD and PsA. For a brief 
focus on potential mechanisms of effect of the oils administrated, the need for 
improved prostaglandin methodology was undertaken. Besides, for a brief focus on the 
impact of diet on the pathogenesis of IBD, an animal model was included. While 
tumour necrosis factor-α (TNF-α) inhibitors have recently been increasingly popular 
for treating inflammatory joint pain, they will not be discussed in this thesis. National 
Institute of Nutrition and Seafood Research (NIFES), the governmental research 
institute under RMFCA, with administrative duties devoted to seafood in human 
nutrition, has collaborated with Haukeland University Hospital (HUH) and University 
of Bergen (UoB) in this interdisciplinary project. Our strategy has been to provide 
generic information about SO and WO, not brand “X” or “Y”, to the whole industry, 
governmental and non-governmental agencies, the research community and relevant 
user groups. Our approach has been documentation of nutrient content in, and health 
effects of, different commercial or non-commercial SO and WO openly, without any 
product development. Oils were either purchased or donated, the latter with no 
contractual limitations as to publication of eventual negative results. Only scientific 
aspects of SO and WO are elaborated on in the present thesis.   
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2.2 Aim of papers 
Paper I: To compare the effects of short-term duodenal administration of SO versus 
soy oil on joint pain in patients with IBD and investigate potential prolonged effects 
during a six month follow-up period. 
Paper II: To investigate whether normalisation of the n-6 to n-3 PUFA ratio in blood 
and tissues by SO is associated with improved HRQOL as assessed by the generic 
short-form 36 (SF-36) questionnaire. 
Paper III: To compare the effects of short-term oral administration of SO versus soy 
oil on disease manifestations in PsA patients. 
Paper IV: To investigate whether prior short-term supplementation with SO, cod liver 
oil or soy oil in addition to standard diet would influence the subsequent development 
of colonic inflammation in response to dextran sulfate sodium (DSS) in rats. 
Paper V: To investigate how simultaneous changes of PGE2 and internal standard (IS) 
concentrations affect the response factor (RF) and how modelling of the relationship 
PGE2/IS can help select an optimal amount of IS in the analysis of plasma PGE2 by 
liquid chromatography tandem mass spectrometry (LC-MSn). 
Paper VI: To compare the effects of short-term duodenal administration of WO versus 
SO on joint pain in patients with IBD. 
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3. Introduction 
3.1 Inflammatory bowel disease 
The two major forms of idiopathic IBD are Crohns’ disease (CD) and ulcerative colitis 
(UC), both chronic enteric inflammatory diseases [9]. Flares with diarrhoea, 
abdominal pain and rectal bleeding in between periods with remission of symptoms 
are common. The aetiology is unknown; however, both genetics and environmental 
factors are involved in the pathogenesis. IBD is seemingly a result of an abnormal 
chronic activation of the mucosal immune system enhanced by luminal bacterial flora 
or alimentary allergens. Defects in the barrier function of the epithelium and the 
mucosal immune system are probably involved [10]. Although CD and UC are distinct 
diseases, they are not discrete, and share much of the same pathophysiology, 
treatment, complication and investigation.  
 CD may affect any part of the gastrointestinal (GI) tract; however only 
separated parts of the GI tract are inflamed (skip lesions of normal bowel wall in 
between inflamed areas). Distal ileum and proximal colon are affected in about two 
thirds of patients, while jejunum, duodenum, stomach and esophagus are infrequently 
affected. All layers of the GI wall may be affected, i.e. transmural inflammation. A 
prevalence of around 1.44 per 1000 has been reported for CD [11]. Indeed, the 
prevalence rates are increasing, particularly in Asia and among Asian immigrants 
living in Europe.           
 UC is characterized by continuous inflammation of the colonic mucosa only. 
Usually, the inflammation is most pronounced in the rectum and sometimes it is 
limited to the distal part of the colon only. A prevalence of 2.29 to 2.43 per 1000 has 
been reported for UC [11]. While not as much as for CD, the prevalence of UC is 
indeed increasing, particularly in Asia and among Asian immigrants living in Europe.
 Figure 1 displays normal mucosa in healthy bowel and inflamed mucosa in CD 
and UC patients, respectively.  
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Figure 1. Normal mucosa in healthy bowel (left), inflamed mucosa in bowel of a Crohns’ disease patient
(middle) and inflamed mucosa in bowel of an ulcerative colitis patient (right). With permission from the 
Norwegian IBD-patient organisation (Landsforeningen mot fordøyelsessykdommer (LMF), Oslo, Norway). 
3.1.1 Rheumatic complications of inflammatory bowel disease 
Extraintestinal manifestations (EIM) can affect virtually every organ system including 
the joints, skin, mouth, liver and eyes and commonly occur in up to 40 % of IBD-
patients and cause significant morbidity and distress for patients [12]. Rheumatic 
complications are the most common EIM, with peripheral arthritis present in 5-20 % 
of patients and axial arthritis (spondylitis or sacroiliitis) commonly present in 3-20 % 
of patients (sacroiliitis reported in up to 43 % of patients), as reviewed [12, 13]. 
Between 5-22 % of IBD-patients have joint pain without arthritis (i.e. arthralgia) [6, 
14], though the prevalence may be higher as such patients are largely ignored due to 
few clinical or laboratory findings. Consequently, such patients are poorly treated 
despite experiencing disturbed sleep, painful joints, morning stiffness and reduced 
HRQOL [6]. 
3.1.2 Experimental models of inflammatory bowel disease 
There are various animal (mainly rodent or murine) models of IBD, both spontaneous 
and induced models of acute and chronic inflammation, as reviewed [15]. Induction of 
experimental colitis by administration of toxic chemicals like e.g. acetic acid, 
indomethacin, trinitrobenzene sulfonic acid/ethanol or polysaccharides like DSS, 
carrageenan or immune complexes are most commonly used. Contrary to IBD in man, 
most of these models are not chronic and colonic healing is rapid [16]. When given in 
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drinking water (2-5 %) to rodents, DSS induce an acute colonic injury, with 
subsequent slow colonic regeneration and chronic colitis. DSS-induced colitis in the 
rat model results in inflammatory changes similar to those found in the colon of UC 
patients. The mechanism by which DSS induces colitis is not precisely known, but 
may involve a toxic effect directly on colonic epithelial cells. 
3.2 Psoriatic arthritis 
PsA is a heterogeneous chronic inflammatory joint disease, with five traditional 
subclasses as described in the initial Moll and Wright criteria [17]. Symmetric 
polyarthritis is increasingly the predominant subclass [18]. PsA is the second most 
prevalent chronic inflammatory joint disease in Caucasians, after rheumatoid arthritis 
(RA), with a prevalence of up to 1.95 per 1000 [18]. Skin and joint inflammation in 
psoriasis are related, but PsA is indeed distinct from psoriatic skin inflammation, as 
arthritis may be present without psoriasis in a few PsA patients [19]. Most PsA 
patients having arthritis also experience psoriasis, while only one fourth of psoriasis 
patients manifest arthritis, as reviewed [19]. Colonic mucosal inflammatory alterations 
[20] or even acute and chronic enteric inflammation [21, 22] are common in PsA 
patients. Interestingly, enteric inflammation may be involved in the pathogenesis of 
spondylarthritides (SpA) like PsA and IBD-associated joint complications [13, 23]. 
Figure 2 displays the hands of a patient with PsA. 
Figure 2. Hands of a patient with psoriatic arthritis. With permission from The Norwegian Psoriasis Federation 
(Norsk psoriasisforbund, Oslo, Norway).
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3.3 Adverse effects of cyclooxygenase-inhibitors 
Non-steroidal anti-inflammatory drugs (NSAIDs) are non-selective COX-inhibitors 
which target prostaglandins [24], as discussed later, widely prescribed and bought 
over-the-counter for rapid and effective treatment of joint pain. Unfortunately, the use 
of NSAIDs and possibly also the new selective COX-2 inhibitors are associated with 
GI adverse effects, e.g. barrier disruption, bleeding and ultimately ulcer disease, 
prompting a cautious use of such drugs [25]. This may particularly apply for IBD-
patients, as COX-inhibitory drugs have been implicated in inducing IBD, activating 
quiescent IBD and exacerbating IBD-disease activity [7, 26]. Besides, the use of 
COX-2 inhibitors and NSAIDs increase the risk of serious adverse effects, e.g. fatal 
cardiovascular events [24, 27], recently resulting in the withdrawal of certain drugs 
from the market [28]. Thus, both IBD and PsA patients need safe alternative or 
adjuvant therapies for joint pain. 
3.4 Nutritional aspects in relation to chronic inflammatory diseases 
While the human genetic pool has remained much the same since the Paleolithic 
period 40 000 years ago (i.e. the birth of our ancestors), our diet has changed 
considerably [1], particularly during the last century. The current Western diet is 
characterised by an increase in total calorie intake (combined with low activity), 
saturated fat, trans-fatty acids, n-6 PUFA and cereal grains and a reduction in complex 
carbohydrates, fiber, protein, antioxidants, calcium, LC n-3 PUFA, fruits and 
vegetables. In the following, mainly n-6 and LC n-3 PUFA, present in vegetable and 
marine oils, respectively, are focused on. 
3.4.1 Dietary fat and fatty acids 
The fats in the human diet provide close to 40% of the energy intake in the Western 
world and the quantitatively most important lipid class is the triacylglycerol (TAG) 
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fraction, which is composed of a glycerol molecule with three FA attached [29]. As a 
result of the agricultural revolution, most of the dietary TAGs have increasingly been 
derived from cheap bulk-produced PUFA rich vegetable oils, particularly soy oil 
which is rich in LA, the precursor of AA [30]. Dietary FA are incorporated into blood 
and tissue cell membranes, which consist of a phospholipid bilayer. There are two 
principal PUFA families, namely the n-6 and the n-3 families, with LA and α-linolenic 
acid (18:3n-3, ALA) the simplest FA respectively [31]. LA and ALA are essential FA 
which need to be provided in the human diet and consequently are the precursors for 
the synthesis of longer chained and more unsaturated n-3 and n-6 PUFA through 
elongation and desaturation processes. The n-6 and n-3 PUFA families compete for 
the elongase and desaturase enzymes, which have greater affinity for substrates with 
many double bonds like n-3 PUFA. However, as a result of a high dietary n-6 to n-3 
PUFA ratio in the Western diet, AA prevails in cell membranes of blood and tissues 
[2] and n-3 PUFAs are naturally less available for the above mentioned enzymes [30]. 
Besides, the in vivo conversion of ALA to EPA, docosapentaenoic acid (22:5n-3) and 
particularly to docosahexaenoic acid (22:6n-3, DHA) are limited in humans [32]. 
Thus, ingestion of preformed LC n-3 PUFAs like EPA, DPA and DHA, commonly 
referred to as “marine” due to their abundance in fatty fish, seafood and marine oils, is 
considered highly important, as reviewed [33]. 
3.4.2 N-6 and long chain n-3 polyunsaturated fatty acids as precursors of eicosanoids 
A high dietary ratio of n-6 to n-3 PUFA may result in an imbalance in the ratio of AA 
to EPA, which is rate limiting for the production of eicosanoids, hormone-like 
metabolic compounds [1]. AA and EPA liberated from cell membranes by 
phospholipases compete as substrate for the synthesis of e.g. prostaglandins and 
thromboxanes by COX and leukotrienes by lipoxygenase (LOX) enzymes, and are 
thus precursors of these eicosanoids. Prostaglandins derived from AA generally induce 
arrhythmia, while the opposite is the case for their EPA derived counterparts. Besides, 
prostaglandins like PGE2 are implicated in pain [24]. In general, leukotrienes derived 
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from AA are more pro-inflammatory than their EPA-derived counterparts, which may 
in fact be anti-inflammatory. In general, thromboxanes derived from AA activate 
platelets and are vasoconstrictors, while thromboxanes derived from EPA are platelet 
inhibitors and vasodilators. Administration of marine oils partially replace AA with 
EPA and DHA in cell membranes, and thereby reduce levels of generally pro-
inflammatory eicosanoids like PGE2 and leukotriene B4 (LTB4) derived from AA [3]. 
Besides, EPA is substrate for less pro-inflammatory eicosanoids like e.g. prostaglandin 
E3 (PGE3) and leukotriene B5 (LTB5). Antagonising AA metabolism through altered 
eicosanoid production is a key anti-inflammatory effect of LC n-3 PUFA, while other 
anti-inflammatory effects dependent or independent of eicosanoid production have 
also been described [3].  
3.4.3 Western diet in relation to pathogenesis of chronic inflammatory diseases 
In an evolutionary aspects, it is notable that the diet of our ancestors had an n-6 to n-3 
PUFA ratio of close to 1:1, while today the ratio is commonly 15-16.7:1 in the 
Western world [34]. The general dietary recommendation over the last 50 years has 
been “to eat some PUFA”, based on limited documentation on potential health 
implications [35]. Indeed, a high dietary n-6 to n-3 PUFA ratio has been linked to the 
increased prevalence of chronic inflammatory diseases like e.g. IBD and RA [36], 
while little is known about diet in relation to the pathogenesis of PsA. Interestingly, a 
high n-6 PUFA intake in early life stages, and even during fetal exposure, may trigger 
an abnormal colonic inflammatory response when exposed to a GI insult later in life 
[37]. In order to possibly slow down and prevent this development of numerous 
chronic inflammatory diseases, lowering the n-6 to n-3 PUFA ratio in our diet is 
essential [30]. Indeed, recently more specific PUFA recommendations like increasing 
the LC n-3 PUFA intake have been enforced [35].  
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3.4.4 Marine oils 
The traditional Eskimo diet contained traditional food, little processed food and 
seafood in general, especially meat and blubber from marine mammals like e.g. seals 
and whales [38]. However, most research has focused on fish oils and particularly its 
high content of EPA and DHA ever since the initial studies by Dyerberg and Bang 
[39]. Interestingly, a low prevalence of common westernized diseases like e.g. IBD, 
bronchial asthma, multiple sclerosis, RA and psoriasis were previously seen in 
Greenland Eskimos [40, 41], while today the Western diet is much more common and 
the prevalence of many typical westernized diseases are increasing [42]. 
 Compared to fish oil, SO and particularly WO contains less EPA and DHA but 
more of DPA, a potent inhibitor of platelet aggregation [43], as confirmed when 
administrating these oils to humans or animals [27, 44, 45]. SO and WO are 
structurally different oils compared to fish oil. EPA and DHA are almost exclusively 
located in the sn-1 or sn-3 (outer) positions of TAG from SO and WO, while these FA 
are located mainly in sn-2 (middle) position of TAG from fish oil [46]. While FA in 
the sn-2 position of TAG are generally preserved (75 %) through digestion and 
absorption [47], and intramolecular distribution of FA in TAG generally do not 
influence tissue uptake [29, 48], sn-1/sn-3 position specific lipoprotein lipases [49] 
may possibly favour peripheral availability of LC n-3 PUFA in outer positions of 
TAG, as seen with PGE2 reduction in rats fed structured TAG [50]. Whether this also 
applies for natural TAGs with complex FA compositions remains to be elucidated.
 Marine oils on the market should as any other food for human consumption 
comply with regulations on contaminants, implying removing the contaminants by 
conventional refining or molecular distillation in the case of marine oils. Such 
processing may negatively influence the level of nutrients, natural antioxidants and 
other bioactive components and consequently the quality of such products [51]. Levels 
of fat soluble vitamins A, D and E are normally reduced during this cleaning process; 
however antioxidants or tocopherols are commonly added for protection of oils against 
lipid peroxidation. Vitamin D is added in some oils, most notably in cod liver oil.   
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3.4.5 Effects of marine oils in some chronic inflammatory diseases  
Long-term oral administration of LC n-3 PUFA has been shown to reduce enteric and 
skin inflammation in clinical studies of IBD [52] and psoriasis [53], respectively, 
however effects are inconsistent. In comparison, fish oil administration generally 
reduces colonic inflammation and damage, weight loss and mortality in animal models 
of colitis [3].          
 Effects on IBD- and PsA-related joint pain have been scarcely studied. In a 
recent open pilot study, short-term (10 days) nasoduodenal administration of SO, 10 
mL × 3 daily, reduced joint pain and IBD-disease activity without adverse effects in 
patients with mild to moderately active IBD [54], while the effect of WO is unknown. 
In a previous study of 80 patients with stable chronic psoriasis, 43 % (34 patients) 
with PsA, joint pain and PASI (Psoriasis Area and Severity Index) scores were 
reduced after 8 weeks administration of capsules with 1.1 g EPA and 0.8 g DHA ethyl 
esters daily [55]. In a later study, patients with chronic stable plaque psoriasis and PsA 
were given Efamol Marine capsules with 480 mg γ-linoleic acid, 240 mg EPA and 132 
mg DHA daily or placebo for 9 months, followed by placebo for three months to both 
groups [56]. No clinical joint or skin effects were seen, possibly due to the low daily 
FA dosage.           
 In RA patients, long-term (at least 3 months) oral administration of fish oil 
moderately reduces joint pain, morning stiffness, number of painful and/or tender 
joints and NSAID consumption [57]. Besides, marine oil administration has beneficial 
cardiovascular “side-effects” [27, 44], suggesting treatment of joint pain may have 
collateral health benefit in RA and possibly PsA patients, which have increased risk of 
cardiovascular disease [58]. Importantly, fish oil is a natural COX-inhibitor which 
clearly outweighs NSAIDs regarding sum of benefit and risk [59]. Still, NSAIDs are 
widely used, while fish oils are scarcely used, possibly due to the latency of effect of 
orally administrated marine oils but also due to marketing issues [4].  
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3.5 Methodology for the analysis of eicosanoids 
Traditionally, the analysis of eicosanoids is performed by using immunological assays, 
e.g. enzyme- or radio-immunoassays. Although immunological assays are inexpensive 
and simple to perform, their main disadvantages are the associated high variability, the 
lack of specificity for complex biological matrices, the potential cross-reactivity and 
consequently the analytes overestimation [60, 61].    
 Single or coupled chromatographic methods are increasingly being used for the 
analysis of eicosanoids [62]. LC-MSn may provide a powerful tool for selectively and 
accurately analysing prostaglandins. However, its major drawback is a limit of 
quantification (LOQ, in ng/ml) higher than those reported by sensitive immunological 
assays (LOQ in pg/ml) and LC-MSn is consequently unable to estimate normal 
occurring endogenous levels of PGE2 in plasma [63]. Although this disadvantage of 
LC-MSn, it is a suitable technique in clinical studies where pathological levels of 
PGE2 are assessed.           
 LC-MSn quantitative studies involving the external standard calibration (a 
technique currently used in immunological assays) and/or a large number of samples 
to be analysed, are impractical, difficult and time consuming and call for compulsory 
construction of several calibration curves. To overcome these problems, the IS 
technique is the preferred approach to attain rapid sample analysis efficiency at a 
minimum cost. The IS approach consists of adding deliberately a compound 
resembling the eicosanoid of interest to the sample. When available, the ideal IS is a 
deuterated analogue of the analytical prostaglandin.  
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4. Material and methods 
4.1 Inflammatory bowel disease studies (papers I, II and VI) 
Consecutive out-patients with IBD, i.e. CD or UC, and joint pain with or without 
arthritis (the latter arthralgia), were recruited at Department of Medicine, Section for 
Gastroenterology and Department of Rheumatology, both HUH, and through the 
Norwegian IBD-patient organisation (LMF, Oslo, Norway). Patients generally had a 
history of joint pain and as clinical effects appeared similar in CD and UC patients, 
these patient groups were pooled and referred to as patients with IBD-related joint 
pain. In papers I, II and VI the patients were randomly allocated to 10 days treatment 
with marine or vegetable oils (10 mL × 3 daily before meals), self-administrated 
through a nasoduodenal feeding tube (Freka® Feeding Tube, Fresenius Kabi, GmbH, 
Germany), with a six month follow-up period in paper I (Table 1). The feeding tube in 
question is 120 cm long and made of polyurethane (2.1 mm internal diameter and 2.8 
mm outer diameter), originally designed for up to 4-6 week enteral nutrition purpose. 
Figure 3 shows a nasojejunal feeding tube, located with its tip in the jejunum, not the 
proximal part of duodenum as in our case. In paper II, control samples were obtained 
during routine biopsies of prostate cancer patients without IBD or joint pain (Table 1). 
                                            
Figure 3. Fluoroscopy image of an inserted nasojejunal feeding tube. With permission from Professor Arnold 
Berstad, University of Bergen/Haukeland University Hospital.
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4.2 Prostaglandin E2 method study (paper V) 
Plasma samples from 21 IBD-patients in paper VI were used in a PGE2 method study. 
Considering the expected variable levels of PGE2 in the clinical samples, it was 
decided to optimise firstly the amount of IS (PGE2d4) using the experimental design 
approach illustrated in Figure 1 of paper V, where blank plasma samples were spiked 
with known amounts of PGE2 and PGE2-d4 and quantified by means of LC-MSn as 
described later. To this aim, the concentrations of PGE2 and IS were varied 
simultaneously as detailed in paper V and the behaviour of the response factor (RF) 
was studied and determined by the expression: 
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RF ×=  (Eq. 1)    
The term ng in Eq. 1 above refers to nanograms of PGE2 and PGE2d4 injected in the 
liquid chromatography system and the term S to the analytical signals monitored in the 
mass spectrometry detector and recorded in ion counts per seconds.  
4.3 Psoriatic arthritis study (paper III) 
Among all PsA patients (n = 634) identified in the county Hordaland, Norway in the 
period 1999-2002 [18], those with polyarticular PsA and seen with active joint disease 
at Department of Rheumatology, HUH during the last year were sent a written request 
to attend 14 days oral administration of marine or vegetable oils (10 mL × 3 daily 
before meals) with a four week follow-up period (Table 1).  
4.4 Experimental colitis study (paper IV) 
Forty-eight adult male Wistar rats were divided into 6 groups: no intervention, sham 
(distilled water), DSS, seal oil + DSS, cod liver oil + DSS and soy oil + DSS (Table 
1). Following one week of acclimatisation, 1 mL oil/day (seal, cod liver or soy) or 
sham was administered by gastric gavage to rats for one week, followed by induction 
of colitis by 5% DSS in drinking water for one week. 
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Table 1. Overview of material, study design and methods in papers I-IV and VI 
 Paper I Paper II Paper III Paper IV Paper VI
Patients/animals IBD-related joint pain 
(n=19) 
1) IBD (n=10, 9 with 
joint pain) and prostate 
cancer (n=10)          
2) IBD-related joint 
pain (n=17)  
PsA (n=40) Adult male Wistar rats   
(n=48) 
IBD-related joint pain 
(n=18) 
Experimental group(s) SO (n=10) 1) SO to IBD-patients   
2) SO 
SO (n=20) SO + DSS (n=8),       
CLO + DSS (n=8),      
VO + DSS (n=8),   
DSS (n=8)  
WO (n=9) 
Control/placebo group VO (n=9) 1) No oil to controls     
2) VO 
VO (n=20) No oil (n=8),         
sham (n=8) 
SO (n=9) 
Mode of oil 
administration         
(daily dosage) 
Duodenal (10 mL × 3) Duodenal (10 mL × 3) Oral (10 mL × 3) Gastric gavage (1 mL) Duodenal (10 mL × 3) 
Duration of oil 
administration                   
+ follow up 
10 days              
+ 1, 2, 4 and 6 month 
1) 10 days            
(IBD-patients)         
2) 10 days            
+ 1, 2, 4 and 6 month 
14 days + 1 month Oils/no oils/sham for 7 
days before DSS-
induced colitis  
10 days       
Joint measures            Morning stiffness;  
tender, swollen and 
painful joints; VAS (3 
different); MHAQ 
Tender and          
swollen joints;       
VAS (2 different); 
MHAQ 
 Morning stiffness, 
painful joints,         
VAS (3 different) 
Intestinal measures     Faecal calprotectin     
+ IBD-index  
 Faecal calprotectin at 
baseline 
Faecal GMP (day 22)    
+ colonic histology 
(day 23) 
Faecal calprotectin      
+ IBD index  
Skin measures              PASI    
Quality of life 
questionnaire 
 2) SF-36   SF-NDI 
Diet assessment 
(baseline) 
Questionnaire on fish 
and LC n-3 PUFA 
supplements 
1) Not performed       
2) Questionnaire on 
fish and LC n-3 PUFA 
supplements 
Habitual intake of 
fish and fish oil 
reported 
Data on standard diet Habitual intake of fish 
and LC n-3 PUFA 
supplements reported 
(diet restrictions) 
Fatty acid analysis      Serum before and after 
treatment 
1) Rectal mucosal 
biopsies before and 
after SO (IBD-patients) 
or one sample from 
controls 
Serum  RBC at day 22  Plasma  
Other measures           Serum TBARS before 
and after treatment 
 -Serum: cholesterol, 
homocysteine, ESR, 
CRP and TBARS     
-Plasma: calprotectin  
-Blinding rate (after)
-DSS intake         
(every other day)       
-BW (day 8, 15, 23)     
-Colon length (day 23) 
-Plasma PGE2         
-Preferences (before)
     
-Blinding rate (after)    
-AE questionnaire      
Paper II: 1) = data from the pilot study on seal oil in IBD [54] and 2) = data from paper I.  Assessments/analysis before and after study and 
during follow-up unless specified. TBARS = thiobarbituric acid reactive substances. ESR = erythrocyte sedimentation rate. CRP = C-
reactive protein. IBD = inflammatory bowel disease. PsA = psoriatic arthritis. VAS = visual analogue scale. MHAQ = modified health 
assessment questionnaire. DSS = dextran sulfate sodium. GMP = granulocyte marker protein. IBD-index = questionnaire on IBD-disease 
activity.  PASI = psoriasis area and severity index. AE = adverse effects. PGE2 = prostaglandin E2. SO = seal oil. CLO = cod liver oil. VO = 
vegetable oil (soy oil). WO = whale oil. BW = body weight. SF-NDI = short-form Nepean dyspepsia index. LC n-3 PUFA = long chain 
omega-3 polyunsaturated fatty acids. 
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4.5 Marine and vegetable oils  
One crude and three refined (conventional process) products of SO were used in the 
clinical and animal studies (papers I-IV and VI). The refined SO was from adult harp 
seals, and the crude SO was a mixture of oil from adult harp and hooded seals, all of 
Canadian origin. The fish oil used in paper IV was a commercially available refined 
(conventional process) cod liver oil and the WO (from adult minke whales) used in 
paper VI was a molecularly distilled (slow speed at 195°C) oil, both Norwegian 
products. As marine mammals are atop the marine food chain, levels of contaminants 
were analysed in all marine oils to satisfy current European Union (EU) regulations on 
contaminants. The contribution of contaminants in oils to the tolerable weekly intake 
(TWI) was estimated before use in clinical studies.      
 While no antioxidant was added to the crude SO (i.e. containing only natural 
tocopherols), a combination of natural and synthetic tocopherols, the latter dl-α
tocopheryl acetate, was added to SO in papers II and III and in cod liver oil in paper 
IV. In paper VI, natural tocopherols were added to SO and dl-α tocopheryl acetate was 
added to WO.           
 Refined commercially available soy oil from one manufacturer was used in 
papers I-IV. See Table 2 for an overview of fatty acids, fat soluble vitamins (A, D and 
E) and lipid peroxidation (thiobarbituric acid reactive substances, TBARS) in the 
marine and vegetable oils used in papers I-IV and VI. Marine oils were stored frozen 
at -20◦ C until used in clinical trials, while soy oil was bought fresh. Oils used in 
clinical trials were distributed in regular polypropylene bottles with nitrogen on top, 
and stored in refrigerator (0-4◦ C) during study.  
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Table 2. Fatty acid profile (g/100 g), vitamins A, D and E and TBARS in experimental oils 
Analyte Crude SOI, II, IV Refined SOII Refined SOIII Refined SOVI Cod liver oilIV Whale oilVI Soy oilI-IV
14:0 4.2 4.4 4.5 4.2 4.0 4.6 n.d 
16:0 
18:0 
∑ saturated 
7.5 
1.0 
12.9 
7.1 
0.8 
12.7 
8.0 
1.2 
14.2 
6.5 
0.8 
12.0 
8.9 
1.8 
15.4 
7.9 
2.0 
15.7 
9.7 
3.0 
13.4 
16:1n-7 
18:1n-11 
18:1n-9 
18:1n-7 
20:1n-11 
11.7 
1.9 
16.3 
3.9 
1.3 
9.7 
1.5 
14.7 
3.4 
1.2 
14 
3.2 
14.9 
3.8 
1.6 
15.7 
3.9 
15.5 
4.0 
1.8 
6.1 
2.0 
13.7 
3.3 
1.6 
5.6 
3.9 
12.5 
4.0 
2.2 
n.d 
n.d 
17.5 
1.3 
n.d 
20:1n-9 
22:1n-11 
7.5 
2.6 
8.1 
3.7 
7.7 
1.8 
9.0 
1.8 
10.2 
7.5 
11.3 
11.2 
0.2 
n.d 
∑ monoenes 47.6 44.2 48.9 53.9 46.0 48.3 19.0 
18:2n-6 1.4 1.5 1.5 1.7 1.5 1.7 49.7 
20:4n-6 0.4 0.4 0.6 0.5 0.4 0.4 n.d 
∑ n-6 1.8 2.1 2.2 2.3 2.2 2.1 49.7 
18:3n-3 0.7 0.8 0.6 0.5 0.8 1.1 5.5 
18:4n-3 
20:4n-3 
20:5n-3 
2.1 
0.5 
6.6 
2.6 
0.5 
5.8 
1.6 
0.5 
7.9 
1.3 
0.5 
6.6 
2.3 
0.7 
7.5 
2.3 
1.4 
3.6 
n.d 
n.d 
n.d 
22:5n-3 3.1 3.3 3.7 3.7 1.1 2.2 n.d 
22:6n-3 7.4 8.9 8.6 7.7 12.4 6.6 n.d 
∑ n-3 21.0 22.1 23.9 21.0 25.1 17.8 5.5 
n-6/n-3 0.1 0.1 0.1 0.1 0.1 0.1 9.0 
Sum vitamin A 
Vitamin D3
1.4  mg/100g 
17 μg/100g 
1.1 mg/100g 
n.a. 
0.3 mg/100g 
n.a. 
n.d 
3 μg/100g 
4.8 mg/100g 
242.7 μg/100g
n.d 
16 μg/100g 
n.d 
15 μg/100g 
α-tocopherol 5.4 mg/100g 5.4 mg/100g 4.5 mg/100g 58.3 mg/100g 309 mg/100g 2.2 mg/100g 17.1 mg/100g 
TBARS 15.3 nmol/g w/w 2 nmol/g w/w 3.6 nmol/g w/w 39.6 nmol/g w/w 13.8 nmol/g w/w 48.7 nmol/g w/w n.d 
Monoenes = monounsaturated fatty acids. Sum vitamin A  = sum retinol  (13-, 11-, 9-cis and all-trans retinol, i.e. A1) and 3,4 didehydro-
all-trans retinol (A2).  TBARS = thiobarbituric acid reactive substances. n.d  = not detected. n.a = not analysed. w/w = wet weight. SO = 
seal oil. Roman numerals in relation to oils refer to which paper (s) they have been used in. Values are mean of two analytical replicates.
32
4.6 Assessments and questionnaires  
As estimates of disease activity, patients reported the mean duration of morning 
stiffness last week (maximum 720 min), i.e. generally how long until musculoskeletal 
stiffness “loosens up”. Using a horizontal visual analogue scale (VAS) ranging from 
zero (very well) to 100 (very poor), various pain or disease activity measures (mean of 
last week) were assessed by patients or a rheumatologist [64].   
 In the clinical IBD-studies, a reduced 28-joint count [65] consisting of 10 
proximal interphalangeal (PIP) joints, 10 metacarpophalangeal (MCP) joints, wrists, 
elbows, shoulders and knees was used for painful (patient assessed), (palpation) tender 
and swollen joints, as assessed by a rheumatologist. In addition to this simplified joint 
count, validated in RA patients [65], ankles and toes (scored as one, i.e. totally 40 
joints) were assessed. In the PsA study, we used the EULAR (European League 
Against Rheumatism) 44 joint count (i.e. the above mentioned 40 joints plus two 
collar bone joints on both sides) [66] together with distal interphalangeal (DIP) joints 
of fingers; i.e. 52 joints in total. Functional level of joint disease was assessed with a 
modified health assessment questionnaire (MHAQ) in papers I and III, with values 
ranging from 1 (no problem to perform) to 4 (impossible to perform) [67]. 
 Harvey-Bradshaw simple index [68] and Walmsley simple clinical colitis 
activity index [69], largely subjective but valuable measures of IBD disease activity 
[70], were used in CD and UC patients respectively. A score equal to or higher than 
six indicates active IBD. Scores for CD and UC disease activity index were pooled in 
results as previously [54, 71]. The PASI score was used for assessing skin 
manifestations in PsA patients, ranging from 0 (no psoriatic lesions at all) to 72 
(complete erythroderma of the severest possible degree), with 0.1 unit steps [72], and 
levels above 10 normally requiring hospitalisation.     
 The Medical Outcome Study (MOS) SF-36 health survey questionnaire was 
used for assessment of HRQOL in paper II [73]. A Norwegian translated version was 
used, validated in RA patients [74, 75]. Final values ranged from 0 (very poor) to 100 
(very well). In paper VI, quality of life (QoL) was assessed with the short-form of the 
Nepean Dyspepsia Index (SF-NDI), originally developed for functional dyspepsia 
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patients [76]. A Norwegian translated version was used, validated in patients with 
food hypersensitivity [77].         
 Background diet was briefly assessed throughout the clinical studies. In paper I, 
a simple self-administered questionnaire on marine food (LC n-3 PUFA supplements 
and fish) was used. Additional results from paper I and from the pilot study [54], the 
latter with no diet evaluation, were presented in paper II. In paper III, patients 
recorded intake of fish and seafood as “never”, “approximately once weekly” or 
“twice or more per week” in addition to LC n-3 PUFA supplements. In paper VI, 
patients’ habitual seafood intake was reported descriptively in brief. In all clinical 
studies, patients were asked to continue their normal Western diet throughout study. In 
the animal study, nutrients in standard diet (pellets) as specified from manufacturer 
were given. Besides, rats were weighed and intake of DSS-water measured. 
 In paper VI, patients were asked about preference before study (i.e. if they 
preferred one particular oil or not) and blinding rate (how many patients who correctly 
identified which oil they received) was assessed in papers III and VI. In paper III, 
those who did not know and those who guessed incorrect were pooled. Self reported 
adverse effects were noted in clinical trials, while additionally a questionnaire on 
adverse effects was answered by patients in paper VI.  
4.7 Laboratory analysis  
Venous blood samples from fasting patients (non-fasting patients in paper III) or 
following exsanguination of fasted rats were collected in vials with no anticoagulant 
(gel vials for serum) or with anticoagulant (for plasma), centrifuged and stored at        
-80◦C prior to analysis of FA composition and PGE2. After centrifugation, before 
storage at -80◦C, plasma for PGE2 analysis was added the COX-inhibitor indomethacin 
(Sigma-Aldrich, Saint Louis, USA); dissolved in ethanol, in a final concentration of 
10 μg indomethacin/mL plasma, within 30 minutes of venupuncture. Replicate 
aliquots of plasma without indomethacin were taken for control.  
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 FA composition of total lipids was analysed by gas liquid chromatography 
(GLC) at NIFES in blood and tissues (for compliance purpose) and marine oils as 
described previously [78], with some modifications as given in papers I-IV and VI. In 
brief, total lipid content was extracted, filtered and evaporated, sample saponified and 
FA were esterified. The methyl esters were separated using a gas chromatograph as 
described in papers I-IV and VI, equipped with a 50 m CP sil 88 (Chrompack) fused 
silica capillary column (id: 0.32 mm), using ”cold on column” injection, with a 
temperature programme of 6025°C/min16025°C/min 19025°C/min220°C5min and flame 
ionization detector. The FA composition was calculated using an integrator 
(Turbochrom Navigator, Version 6.1), connected to the GLC and identification 
ascertained by standard mixtures of methyl esters (Nu-Chek, Elyian, USA). 
Nonadecanoic acid (19:0) methyl ester was used as IS for quantitative determination 
of FA. LOQ was 10 μg FA/g sample (wet weight, w/w). 
 In paper VI, PGE2 was extracted from plasma with and without added 
indomethacin and analysed by using a LC-MSn method developed at NIFES for the 
analysis of this analyte in human plasma [79] with modifications given in paper V. 
The method involves precipitation of the protein fraction, centrifugation, evaporation 
and dissolution of the supernatant in acetonitrile and quantification by liquid 
chromatography ion trap mass spectrometry (LCITMS). The LCITMS used was an 
Agilent 1100 series LC/MSD trap, SL model with an electrospray interface (ESI). A 
Zorbax Eclipse-C8 RP 150 × 4.6 mm, 5 μm (Agilent Technologies, Palo Alto, CA, 
USA) column held at 40 C° with acetonitrile isocratic mobile phase at 0.2 mL/min and 
25 μl injection volume were used. The ESI source was operated in negative ion mode, 
isolating and fragmenting the m/z 351 → 333, 315, 271 for PGE2. Software used was 
ChemStation for LC/MSD version 4.2 from Agilent. PGE2-d4, the deuterated 
analogue of PGE2, was used as IS. LOQ was 0.4 ng PGE2/ml. 
 In paper III, erythrocyte sedimentation rate (ESR) was analysed according to 
Westergren method, C-reactive protein (CRP), total plasma homocysteine, total-, high-
density lipoprotein (HDL) - and  low-density lipoprotein (LDL)-cholesterol (all three 
Roche Modular enzymatic kits) were analysed by routine methods at Laboratory of 
35
Clinical Biochemistry, HUH. Plasma calprotectin was analysed by enzyme-linked 
immunosorbent assay (ELISA) at Ullevaal University Hospital, with a reference 
interval of 100-900 μg/L [80]. Calprotectin is a calcium- and zinc-binding protein, and 
blood levels of calprotectin reflects disease activity in PsA and other arthritides [81].
 Faecal calprotectin, a non-invasive biomarker of IBD disease activity, was 
analysed in frozen spot samples of faeces in clinical IBD-studies and PsA study by 
ELISA, at the Section for Gastroenterology, Institute of Medicine, UoB. Calprotectin 
is the main soluble protein present in neutrophil granulocytes, monocytes and 
macrophages in the intestine [82]. Generally, a faecal calprotectin value above 50 
mg/kg is abnormal, but in clinical practice, only values above 500 mg/kg indicate 
active IBD [82].           
 Faecal granulocyte marker protein (GMP), a rat counterpart of human 
calprotectin, was analysed by ELISA, as a marker of disease activity in experimental 
colitis, with levels up to 25 mg/L considered normal [83]. Histological assessment of 
colonic crypt and inflammatory scores in formalin fixed, paraffin-embedded colonic 
segments, stained with haematoxylin and eosin, were done according to a validated 
scoring system [84] after recording the length of the colon.     
 Vitamin A, i.e. sum retinol  (13-, 11-, 9-cis and all-trans retinol, i.e. A1) and 3,4 
didehydro-all-trans retinol (A2), were analysed in marine oils at NIFES by a modified 
high performance liquid chromatography (HPLC) method [85, 86]. Briefly, the sample 
is saponified, while the unsaponified sample material is extracted, and analysed by a 
HPLC column (HICHROM 4,6 × 150 mm, LC-SI, 3μm, Teknolab A/S) using ultra 
violet (UV)-detector (Thermo Separations products, UV1000, Instrument-Teknikk 
AS), with reference to an external standard curve. LOQ in oils was 280 ng vitamin 
A1/g sample and 460ng vitamin A2/g sample, both w/w.   
 Vitamin D in marine oils was analysed at NIFES by HPLC as described 
previously [87]. In brief, sample material is saponified and the unsaponified material 
is extracted before clean-up on a preparative column (HICHROM, Kromasil silica, 5 
μm, 4.6 × 250 mm). The fractions with vitamin D2 (ergocalciferol) and D3
(cholecalciferol) are collected (normal phase), evaporated and dissolved in methanol, 
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before injected on an analytical column (Ace 5 C18, 5 μm, 4.6 × 250 mm), (reverse 
phase). Vitamin D3 was determined by UV-detector (LaChrom, Merck HITACHI L-
7420) and quantified using vitamin D2 as IS. LOQ was 1 μg vitamin D3/100 g sample 
(w/w).           
 Vitamin E in marine oils was analysed at NIFES by HPLC, based on the 
principles reported by European Committee for Standardization (CEN) [88]. Briefly, 
sample is saponified and unsaponified sample material is extracted. α-, β-, γ- and δ-
tocopherol isomers were determined using a HPLC column (LiChroCART, 4,6 × 125 
mm, Purospher STAR Si, 3 μm, Merck) equipped with a fluorescence detector (TSP, 
FL3000, Spectra system) and quantified by reference to an external standard curve. In 
our case, only α-tocopherol was reported. LOQ in oils was 500 ng α-tocopherol/g 
sample (w/w).         
 TBARS was analysed in serum and marine oils at NIFES by a modified in vitro 
method, measuring mainly malondialdehyde and other aldehydes, secondary lipid 
peroxidation parameters  [89, 90]. In brief, fat and water-soluble components are 
separated, while the analyte is extracted in a methanol:water phase. An aliquot of the 
latter phase is added thiobarbituric acid (TBA) in excess and heated to form a coloured 
complex between aldehydes in the sample and TBA. The absorption at 532 nm was 
registered and TBARS was quantified by reference to an external standard curve in a 
spectrophotometer. LOQ was 3.9 nmol TBARS/g sample (w/w). Serum TBARS 
values in PsA patients were generally below LOQ and therefore not reported in paper 
III.  
4.8 Statistics  
Data were presented and normality tested as detailed in papers. Generally, group 
differences were compared by unpaired Student’s t-test or Mann Whitney, while 
paired differences were evaluated by paired t-test or Wilcoxon sign rank test. In papers 
I and II, area under the curve (AUC) for the entire period from start of treatment until 
6 months post-treatment was calculated with the trapezoid method. In paper III, 
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monovariate associations between variables were analysed using the Spearman rank 
order correlation test. In paper IV, differences between means were evaluated with 
one-way ANOVA (analysis of variance) and post-test (Bonferroni) for selected pairs 
of columns. In paper V, a multiple regression analysis was performed and the 
statistical significance of the coefficients and the correlation was determined by the F-
test. Descriptive statistics was used when appropriate. Except for a 99 % confidence 
level in paper III, P values < 0.05 were generally regarded as statistically significant. 
Statistical data-analysis and displaying of figures were performed using the GraphPad 
Prism 4 (GraphPad Software Inc, San Diego, USA) statistical software package in 
papers I, II, IV and VI. In paper III, SPSS release 13.0 software (SPSS Inc., Chicago, 
USA) was used and in paper V, Statgraphics Plus 5.1 software package (Statpoint Inc., 
Virginia, USA) was used for statistical data-analysis. Microsoft®Excel 2002 
(Microsoft Corporation, Washington, USA) was used for displaying of figures in 
paper V. 
4.9 Ethics 
The clinical trials (papers I-III and VI) were performed according to the Declaration of 
Helsinki, after approval from the Regional Committee for Medical Research Ethics 
and written informed consent from patients (also from the parents of one adolescent 
included in paper I). An application was sent to the Norwegian Social Science Data 
Services regarding data protection, and biological samples were stored in an approved 
research biobank at NIFES. The blood samples obtained from patients in paper VI 
were approved for research, and used during method development in paper V. The 
animal study (paper IV) was performed by Federation of European Laboratory Animal 
Science Associations (FELASA) trained personnel in accordance with The Norwegian 
Animal Welfare Act after approval from the Norwegian Animal Research Authority. 
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5. Results     
5.1 Paper I: Serum ratios of n-6 to n-3 PUFA and AA to EPA were reduced after 10 
days duodenal administration of SO. Compared with similar administration of soy oil, 
SO significantly reduced the duration of morning stiffness, number of tender joints, 
intensity of pain and the doctor’s scoring of rheumatic disease activity. AUC for the 
entire period from start of treatment until 6 months post treatment, suggested a long-
lasting beneficial effect of morning stiffness, MHAQ and doctor’s scoring of 
rheumatic disease activity after SO administration, while soy oil administration tended 
to aggravate the condition (not significantly). No patients had faecal calprotectin 
levels above 50 mg/kg at inclusion, while one patient in the SO group had a value of 
76 mg/kg after treatment.  
5.2 Paper II: In the pilot study [54], 10 days duodenal administration of SO 
normalised  ratios of n-6 to n-3 PUFA and AA to EPA in rectal mucosa of IBD-
patients compared with levels found in controls. Similar administration of SO reduced 
the bodily pain dimension of HRQOL compared with soy oil in paper I. 
5.3 Paper III: There was a fall in the ratios of n-6 to n-3 PUFA and AA to EPA in 
serum after 14 days oral treatment with SO, but no effect on joint pain or skin 
affections compared with soy oil. Patients in the SO group reported a significant 
improvement in global assessment of the disease four weeks post-treatment, with no 
significant group differences. At four weeks post-treatment, non-significant tendencies 
of decreased tender joint count were seen in both groups (P < 0.05) and a non-
significant tendency of decreased swollen joint count was seen in SO group (P < 
0.05), with no significant group differences. 23 % of patients had elevated values of 
faecal calprotectin suggestive of nonactive asymptomatic colitis (no values above 110 
mg/kg), with no difference between patients using NSAIDs and not (P = 0.6). 
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5.4 Paper IV: The ratio of n-6 to n-3 PUFA was 11 to 1 and 10 to 1 in standard diet 
and in red blood cells (RBC) of control rats, respectively. Following administration of 
DSS for 7 days, the ratio in RBC fell in all treatment groups. The lowest ratios were 
seen in the groups receiving DSS + fish or seal oils (around 6 to 1), but 7 days 
pretreatment with these oils did not significantly influence the subsequently DSS-
induced colitis. In fact, all the oils tended (not significantly) to exacerbate the 
inflammation. Soy oil increased the mean crypt score. 
5.5 Paper V: Different RF values were estimated in the entire PGE2 range studied 
(0.0125-0.375 ng) at an IS concentration level (0.0125 ng) equivalent to 1/3 of the 
total PGE2 calibration range, suggesting that the interaction eicosanoid/IS is an 
important factor that affects the validity of the RF and consequently the accuracy of 
plasma PGE2 analysis. By applying a systematic and simultaneous experimental design 
approach, it is possible to estimate a constant RF of 0.075 and perform a reliable 
eicosanoid quantification using an amount of IS between 0.345 and 0.375 ng. 
5.6 Paper VI: Short-term (10 days) duodenal administration of WO or SO reduced  
ratios of n-6 to n-3 PUFA and AA to EPA and PGE2 levels in plasma (tendency with 
WO), with no significant group differences. Correspondingly, joint pain and IBD-
disease activity were reduced and QoL was improved in both groups, with no 
significant group differences. 
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6. Discussion
6.1 Effects of marine oils in inflammatory bowel disease and psoriatic arthritis  
While COX-inhibitory drugs rapidly ameliorate joint pain [27], adverse effects limit 
their use, particularly in IBD-patients [7], enforcing the need for safe adjuvant or 
alternative treatments.         
 In papers I and VI, 10 days duodenal administration of SO or WO both reduced 
IBD-related joint pain (with prolonged effects of SO in paper I), while IBD-disease 
activity (index) was slightly reduced, consistent with findings in our pilot study [54].  
Faecal calprotectin did not change in patients with moderate IBD-disease activity as 
shown previously [54, 71], suggesting no adverse effects of oil administrations. IBD-
patients generally have poor HRQOL [91], and associated joint pain contributes 
considerably [6]. SO improved the bodily pain dimension of HRQOL according to the 
generic SF-36 questionnaire in paper II and both SO and WO improved QoL 
according to the stomach specific SF-NDI questionnaire in paper VI. In comparison, 
when given orally for 14 days (10 mL × 3 daily) to patients with IBD-related joint 
pain, SO did not reduce joint pain or IBD-disease activity compared with cod liver oil 
[71].           
 Correspondingly, long-term oral administration of fish oil is necessary for 
beneficial effects in RA patients [4]. Similarly, 14 days oral administration of SO in 
paper III did not reduce joint pain or skin affections in PsA patients, while no 
significant adverse effects of oil administration were seen. The improvement in 
patients’ global assessment of disease four weeks post treatment in SO group was 
probably due to reduction in symptoms not assessed, e.g. morning stiffness, fatigue or 
disturbed sleep. These results are in accordance with previous studies of LC n-3 PUFA 
administration in PsA documenting no effect [56] or delayed effect [55]. 
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6.2 Experimental colitis study 
A high dietary ratio of n-6 to n-3 PUFA may be involved in the pathogenesis of IBD, 
as reviewed [92]. In paper IV, soy oil increased the mean crypt score, a notable early 
feature of DSS induced damage [93], consistent with its supposedly pro-inflammatory 
effects due to high LA levels [94]. Pre-treatment with SO or cod liver oil did not 
protect against subsequent DSS-induced colitis in rats. Indeed both marine oils tended 
to exacerbate the DSS-induced colitis as seen previously with LC n-3 PUFA [95], 
possibly in part due to stress associated with gastric gavage feeding as discussed in 
paper IV. Mixing the oils into the diet would avoid the need for such force feeding. 
Unfortunately, disease activity index [96] and assessment of rectal bleeding were not 
included in paper IV. 
   
6.3 Oil dosage and contents  
EPA and DHA are presumably the main bioactive components in marine oils [3], 
giving reason for the use of highly purified LC n-3 PUFA capsules, e.g. free FA or 
ethyl esters. In the present thesis, natural TAG oils were preferred, as they may contain 
other beneficial FA and fat soluble vitamins as described later. Interestingly, capsules 
with LC n-3 PUFA in the form of free FA were not effective in recent EPIC (Epanova 
Program in Crohn's Study) trials in CD patients [97].     
 An anti-inflammatory dosage of minimum 2.7 g EPA+DHA daily is moderately 
effective in long-term treatment of RA, ideally with a concomitant low n-6 PUFA 
intake [4]. While no dose-response trial was performed, the 30 mL daily oil dosage 
used in papers I-III, VI and previous studies [54, 71, 98], provided a medium high 
daily dosage of EPA+DHA (3.1 g for WO and between 4.2 to 5 g for SO). SO and 
WO also provided a daily dosage of 0.9 to 1.1 g and 0.7 g DPA, respectively. 
Interestingly, plasma phospholipid DPA was recently found to correlate inversely with 
CRP in patients with active IBD [99]. SO and WO also provided 0.35 to 0.7 g and 0.6 
g stearidonic acid daily, respectively, possibly weighing partially up for the low EPA 
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content compared with fish oil [100]. Notably, SO and WO provided 11.9 to 14.6 g 
and 13.1 g sum monounsaturated fatty acids (MUFA) daily, respectively, and oleic 
acid (18:1n-9) constituted 4 to 4.4 g and 3.4 g per day in SO and WO groups, 
respectively.          
 Vitamin D deficiency is common in rheumatic out-patients [101] and IBD-
patients [102]. Interestingly, mice lacking vitamin D receptor may develop colitis 
[103], but vitamin D deficiency is likely to be consequential rather than causal in IBD 
[92]. Indeed vitamin D supplementation may benefit CD patients [104] and vitamin D 
drugs are used in psoriasis [53]. Slightly reduced IBD-disease activities (indexes) were 
seen after duodenal administration of crude SO providing 61 % and soy oil providing 
55 % of recommended daily allowance (RDA) vitamin D in paper I and after duodenal 
administration of refined SO providing 11 % and WO providing 57 % RDA vitamin D 
in paper VI. However, administration of crude SO or cod liver oil, extremely rich in 
vitamin D, had no protective effect on colitis (paper VI), nor had refined SO or cod 
liver oil any effect on IBD-disease activity when given orally in IBD-related joint pain 
[71]. Unfortunately, serum 25-hydroxyvitamin D (25(OH)D), a biomarker of vitamin 
D status, was not assessed in the clinical trials.      
 Indeed we have no direct comparison with refined SO, however crude SO 
seemed to have a strong effect in paper I. Enforcement of new limits for contaminants 
in marine oils for human consumption in the summer of 2002 prohibited further use of 
crude oils in clinical trials. Refining of marine oils may remove beneficial nutrients, 
antioxidants and other bioactive compounds [51], and particularly cold-pressed WO, 
i.e. normally not heated above 80°C, may have strong anti-inflammatory effects [42, 
44]. However, beneficial effects were still seen with refined SO in the pilot study [54] 
and paper VI, and with molecularly distilled WO in paper VI. 
6.4 Mode of oil administration  
It is acknowledged that oral administration of marine oils is a long-term strategy [27], 
as emphasised in an editorial on paper III. However, many of our patients clearly need 
43
safe analgesics on demand. Although no direct proof of concept concerning the 
superiority of duodenal over oral administration of marine oils exists, papers I, II and 
VI and our pilot study [54] suggest that duodenal administration may act as a rapid 
booster strategy for the relief of joint pain. In a previous study, short-term duodenal 
administration of SO also reduced stomach pain in patients with subjective food 
hypersensitivity [98].        
 Intubation as performed in papers I, II and VI is invasive and uncomfortable, 
but was astonishingly well accepted in patients with IBD. While duodenal intubation 
is a useful and not uncommon procedure in patients needing enteral nutrition or 
endoscopy, rheumatic patients in general are less familiar with the procedure and tube 
fed marine oils was not as feasible in our PsA patients as in our IBD patients. 
Duodenal administration is neither feasible for long-term treatment, thus a 10 day 
study period was considered a compromise between discomfort and benefit. Tube 
feeding ensures correct dosing and targeted delivery and potential reflux with nausea 
and vomiting may also be reduced when three proximal GI sphincters are passed 
[105].           
 Bolus dosages of 10 mL duodenally administrated marine oils may challenge 
the digestive and absorptive capacity of the intestine, and possibly thereby influence 
intestinal mucosal defence. Hydrophobic phospholipids, rich in phoshatidyl-choline 
(PC), floating on top of the mucous layer, is considered an important mechanism by 
which mucosal surfaces resist attacks from noxious, water-soluble substances [106]. 
Interestingly, retarded release PC administration appears effective in the treatment of 
UC patients [107, 108] and enteric coated capsules with LC n-3 PUFA designed for 
distal delivery have prophylactic effect in adult [109] and pediatric CD patients [110].
 Indeed dietary oils may influence gut microbiota [111] and possibly 
consequently joint pain [112]. However, the reduced joint pain by marine oils in 
papers I, II and VI was largely independent of IBD-disease activity consistent with 
previous studies [54, 71] and SO did not improve gut permeability in our pilot study 
[54]. Duodenal administration may also strongly stimulate vago-vagal anti-
inflammatory reflexes, inhibiting the release of pro-inflammatory cytokines like TNF-
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α and interleukin 6, as reviewed [113]. Hence, there are several possibilities of 
improved effect by duodenal administration of marine oils. 
6.5 Fatty acid incorporation and eicosanoid production
Reduced ratios of n-6 to n-3 PUFA and AA to EPA in blood or tissues were seen after 
marine oil administration in patients with IBD- and PsA-related joint pain (papers I-III 
and VI) suggesting putatively anti-inflammatory changes.    
 Tube fed marine oils does not seem to yield a higher incorporation of LC n-3 
PUFAs into blood and tissues than corresponding oral administration, but the latter 
may have effects in PsA (paper III) and possibly IBD-related joint pain [71] given a 
longer treatment period [27]. A longer pre-treatment with marine oils to rats in paper 
IV would probably allow a proper fatty acid incorporation into colonic mucosal cell 
membranes and possibly result in a protective effect on subsequent DSS-induced 
colitis, as shown previously [3]. Ideally, lipid classes and their fatty acid profiles in 
blood and tissues ought to be analysed in future studies. 
 While eicosanoids were not assessed in paper III,  LTB4 levels were previously 
reduced after Efamol marine administration in PsA patients followed by an increase 
during placebo administration [56]. Also, a rise in serum thromboxane B2 (TXB2) was 
seen during the placebo period in the Efamol marine group. Recently, 14 days oral 
administration of SO and cod liver oil both reduced plasma LTB4 in IBD-patients with 
joint pain [71]. While LTB4 may be directly involved in IBD pathogenesis, the role of 
PGE2 in IBD is less established, and it may even be protective for the gut mucosa [3].
However, reduced synthesis of nociceptive circulatory PGE2 levels due to COX-
inhibition is considered a potential mechanism by which marine oils as well as COX-
inhibitory drugs ameliorate joint pain [4, 24]. Decreased levels of PGE2 in colonic 
mucosa [114] and blood mononuclear cells [115] have also been seen after long-term 
oral administration of fish oil in IBD. In a previous study, administration of 15 mL of 
a combination of SO and cod liver oil daily for 10 weeks reduced blood PGE2 levels in 
healthy volunteers [46].         
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 Paper VI indicates for the first time reduced PGE2 levels after SO 
administration alone in IBD-related joint pain and a tendency of reduced PGE2 levels 
after WO administration as well, suggesting that COX-inhibition might be a general 
effect of marine oil administration. As α-tocopherol reduces the release of AA from 
phospholipids [116], the 30 times lower α-tocopherol level in WO compared with SO 
in paper VI, together with low EPA content, may explain the non-significant trend of 
WO on PGE2 production. The large duodenally administrated dosage and the 
positional distribution of LC n-3 PUFA on TAG [50] may possibly explain such a 
rapid reduction in PGE2 levels. However, as no fish oil group was included in clinical 
trials, the full impact of sn-1 or sn-3 versus sn-2 positional distribution of LC n-3 
PUFA in marine oils on peripheral availability of these fatty acids and their effects 
upon eicosanoid production remains to be elucidated.  
6.6 Oxidative stress 
As oxidative stress is increased in chronic inflammatory diseases [117], administrating 
PUFA rich oils, highly prone to lipid peroxidation, may potentially exaggerate the 
stress. Olive oil, particularly extra-virgin type, is protective against oxidative stress 
[118]. While fish oil, SO and WO does not contain as much MUFA, particularly oleic 
acid, as olive oil, the relatively high content of these FA, known to be very resistant to 
lipid peroxidation, may possibly be an advantage of marine oils over purified LC n-3 
PUFA capsules. Indeed, serum TBARS levels did not increase during oil treatments in 
IBD-patients or PsA patients (papers I and III), consistent with previous SO studies 
[54, 71]. In addition to TBARS, it would be advisable to analyse prostaglandin F2α
(PGF2α), also a biomarker of oxidative stress, in blood or urine [119]. While no 
recommended limits for TBARS in oils exist, oils did not appear rancid based on 
smell, taste and appearance. However, including analysis of anisidine and peroxide 
values in oils, primary and secondary parameters of lipid peroxidation with 
recommended limits, would be advisable. 
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6.7 Placebo, blinding and pain issues  
Placebo effects are inherent in any clinical intervention, particularly when assessing 
analgesic effects [120] in uncontrolled studies like our pilot study [54]. When 
administrating natural TAG oils, finding an adequate placebo is a challenge. While 
soy oil may not be considered an inert placebo, vegetable oils are widely used in 
Western diets [1] and was considered in this context an acceptable control oil in 
papers I-III. Clear differential effects of SO and soy oil given duodenally in a double 
blind set up in papers I and II, and the unexpected tendency of increased joint pain 
with soy oil in paper I, prompted the use of SO as “active” control group in paper VI, 
limiting the use of placebo as recommended in the Helsinki Declaration.  
 Oil preferences did not predict outcome in paper VI, suggesting that response 
expectations had minor influence on the relative effects of SO and WO. Whether the 
characteristic smell of the crude SO and the tendency of adverse effects of soy oil may 
have contributed to a minor blinding bias in paper I is unknown, as blinding rate was 
not assessed. When administrating refined marine oils, 37.5 % and 78 % of patients 
were blinded in papers III and VI, respectively. While the former blinding rate may be 
acceptable, the higher latter blinding rate may reflect similar appearance, smell and 
taste of SO and WO. Administrating capsules would possibly ensure enhanced 
blinding rate, but this was not feasible in our setting.     
 Of the IBD-patients in papers I and VI respectively, only 10 of 19 (53 %) and 
four of 18 (22 %) had arthritis. While arthritis is a more severe condition than 
arthralgia, and consequently possibly more difficult to treat, joint pain is a mutual 
symptom in IBD, RA and PsA patients. Interestingly, effects of oil administrations 
seemed equal in patients with and without arthritis in papers I and VI. As pain is 
importantly the fifth vital sign in clinical medicine [121], joint pain undeniably 
deserves attention and adequate treatment irrespective of arthritis. While more 
comprehensive alternatives are being introduced [122], VAS scores are simple but 
reliable ways of measuring pain [123], widely used together with HRQOL for 
assessing analgesic drug effects. Joint effects were ascertained by a rheumatologist in 
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paper I and plasma PGE2 levels were reduced after oil treatment in paper VI, 
supporting a real effect of the marine oils.  
6.8 Faecal calprotectin levels in psoriatic arthritis patients 
At least 15 % of PsA patients have acute or chronic enteric inflammation [21, 22], 
predominantly those with axial disease. In paper III, as many as 23 % of PsA patients, 
none with axial disease, had elevated calprotectin levels in stool suggestive of 
asymptomatic, inactive colitis. Importantly, for confirmation of enteric inflammation, 
other intestinal measures including endoscopy with histology of intestinal biopsies are 
required. Interestingly, 44 % of mainly RA patients on NSAIDs had increased 
calprotectin levels in stool, with high levels also found in healthy volunteers, 
suggesting NSAID induced enteropathy [124]. However, faecal calprotectin levels did 
not differ between those taking NSAIDs and not in paper III, though most PsA 
patients (85 %) used such drugs. In comparison, one IBD-patient (5 %) and three IBD-
patients (17 %) used NSAIDs in papers I and VI, respectively. In general, whether 
NSAIDs or the rheumatic disease is responsible for the enteropathy in SpA like PsA, 
is uncertain [19, 124]. As recommended in an editorial on paper III, a 
multidisciplinary approach involving a dermatologist, rheumatologist and 
gastroenterologist may be recommended for PsA patients [125]. This may possibly 
also apply for IBD patients having frequent joint and skin affections [12]. 
6.9 Choice of internal standard amount in eicosanoid quantification  
Although numerous articles describe the quantification of PGE2 using the IS method, 
few explain how the amount of IS added to the samples was determined. Usually, the 
amount of IS added to the samples is carried out by trial and error methods or rule of 
thumb techniques such as targeting the IS to the lower 1/3 of the calibration curve. In 
addition, despite the fact that the validity of the IS method relies on assumptions of 
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linearity of the detector response towards both the analyte and IS, information about 
the latter is commonly unacknowledged. Regardless of the analyte, the concentration 
ratio analyte/IS could affect the quantitative determination by LC-MSn [126, 127], but 
unfortunately such a relationship is generally ignored. NIFES has recently proposed a 
general experimental design approach for determining a range where the RF does not 
change with the concentrations of analyte and IS [128].     
 Notably, a fixed level of 0.125 ng IS (corresponding to the lower 1/3 of the 
PGE2 calibration curve as recommended by some orthodox approaches) provides 
seven different RF (0.025-0.085) when the amount of PGE2 is varied between 0.013 
and 0.4 ng (Figure 2 in paper V), while a constant RF (0.075) is obtained in the 
previous analytical range (0.013-0.4 ng of PGE2) when the IS is varied between 0.345 
and 0.375 ng. Thus, paper V demonstrates that the application of experimental design 
enables estimating the interaction PGE2/IS and to select confidently an optimal 
amount of IS and a RF for analysing eicosanoids in a high number of samples, where 
the amount of sample is limited and the unknown levels of eicosanoids are spanned in 
a wide range of concentrations.  
6.10 Limitations and future perspectives  
A small and slightly heterogeneous IBD-group may have contributed to baseline group 
differences in papers I and VI. Interestingly, the groups with significantly worse 
baseline joint status had the lowest intake of fish and marine oils and the lowest tissue 
levels of LC n-3 PUFA at baseline (significantly lower in paper I). Indeed a higher 
baseline LC n-3 PUFA status may predict a less effect of LC n-3 PUFA treatment 
[129]. If feasible, screening patients in advance or allowing a run-in period to 
normalize baseline levels, as in paper VI, might be advisable.   
 As vitamins D and E in administered oils may possibly influence on effects 
measured, it would be advisable to adjust levels and use similar antioxidant. A more 
extensive background diet assessment might reveal other nutrients of importance for 
outcome [130]. Ideally, including fish and other seafood in the diet, good sources of 
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LC n-3 PUFA in addition to other beneficial nutrients like e.g. vitamin D, selenium, 
iodine, vitamin B12, taurine and well balanced protein may possibly be beneficial for 
PsA and IBD patients [53, 131]. Besides, as the bioavailability of LC n-3 PUFA may 
depend on the dietary source [132], research on the impact of fish versus various 
dietary supplements is advisable.        
 Mechanisms of effect of SO and WO were only briefly assessed, thus future 
studies should analyse e.g. cytokines (particularly TNF-α as reviewed [125]), nuclear 
factor (NF)-kappa B, resolvins [133] and other eicosanoids in specific cells or tissues. 
In particular, more research on the effects and mechanisms of duodenal versus oral 
administration of marine oils is necessary. As the clinical studies were explorative 
pilot studies, effects in IBD-studies and potential delayed effects in PsA study should 
be confirmed in larger, double blind randomized controlled trials with long-term oral 
administration of SO, WO and fish oil.  
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7. Conclusions
7.1 Individual papers 
Paper I: As short-term duodenal administrations, SO significantly relieved IBD-related 
joint pain with prolonged effects compared with soy oil.  
Paper II: As short-term duodenal administration, SO normalised n-6 to n-3 FA ratio in 
rectal biopsies and reduced HRQOL in patients with IBD-related joint pain. 
Paper III:  
As short-term oral administrations, SO did not improve joint or skin manifestations in 
PsA compared with soy oil.  
Paper IV: Short-term pre-treatment with SO, cod liver oil or soy oil in addition to 
standard diet did not protect against DSS-induced colitis in rats.  
Paper V: The interaction PGE2/IS is an important factor that affects the validity of the 
RF and consequently the accuracy of the analysis of PGE2 by LC-MSn. 
Paper VI: 
As short-term duodenal administrations, WO and SO appear equally effective in 
reducing IBD-related joint pain, possibly in part mediated by COX-inhibition, as 
suggested by reduced PGE2 levels. 
7.2 Overall conclusion 
The thesis suggests that short-term duodenal administration of oils from marine 
mammals, like SO and WO, reduce joint pain and IBD-disease activity and improve 
QoL without significant adverse effects in IBD-patients with moderate disease 
activity, while short-term oral administration of SO does not improve joint or skin 
affections in PsA patients. 
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Errata 
Paper I: 
Correct institutional association of co-authors are NIFES; Institute of Medicine, 
University of Bergen and Haukeland University Hospital.  
Under Methods, MHAQ values should range from 1 (no problem to perform) to 4 
(impossible to perform). 
In Table II the TBARS-denomination in the seal oil should read WW. The last 
sentence in the corresponding table text should be changed to “WW = wet weight.” 
Sum vitamin A in the corresponding table text should read sum retinol (13-, 11-, 9-cis 
and all-trans retinol, i.e. A1) and 3,4 didehydro-all-trans retinol (A2). 
Under Statistics, sentence 5 should read: “Normality of data was tested with the 
Kolmogorov-Smirnov test.” 
The following references should read: 
Reference 2: “Holden W, Orchard T, Wordsworth P. Enteropathic arthritis. Rheum 
Dis Clin North Am 2003;29:513-530, viii.” 
Reference 5: “Thomas PD, Keat AC, Forbes A, Ciclitira PJ, Nicholls RJ. 
Extraintestinal manifestations of ulcerative colitis following restorative 
proctocolectomy. Eur J Gastroenterol Hepatol 1999;11:1001-5. 
Reference 15: “Brox J, Olaussen K, Østerud B, Elvevoll EO, Bjørnstad E, Brattebog 
G, Iversen H. A long-term seal- and cod-liver-oil supplementation in 
hypercholesterolemic subjects. Lipids 2001;36:7-13.” 
Reference 16: “Brockerhoff H, Hoyle RJ, Hwang PC, Litchfield C. Positional 
distribution of fatty acids in depot triglycerides of aquatic animals. Lipids 1968;3:24-
9.”  
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Reference 21: “Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. 
Assessment of patient satisfaction in activities of daily living using a modified 
Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.” 
Reference 22: “Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. 
Lancet 1980;1:514.” 
Reference 34: “von Schacky C, Fischer S, Weber PC. Long-term effects of dietary 
marine n-3 fatty acids upon plasma and cellular lipids, platelet function, and 
eicosanoid formation in humans. J Clin Invest 1985;76:1626-31.” 
Reference 35: “Kinsella JE. Lipids, membrane receptors, and enzymes: effects of 
dietary fatty acids. J Parenter Enteral Nutr 1990;14:200S-17S.” 
Paper II: 
Correct institutional association of co-authors are NIFES; Department of Biomedicine, 
University of Bergen; Institute of Medicine, University of Bergen and Haukeland 
University Hospital.  
Paper III: 
Table 3: Calprotectin concentration should read microgram/L, not mg/L.  
 Nine of the original 43 patients (21 %) included had elevated levels of faecal 
calprotectin, and nine of the 40 patients (23 %) finishing the study had elevated levels 
of faecal calprotectin.  
MHAQ refers to modified health assessment questionnaire. MHAQ values range from 
1 (no problem to perform) to 4 (impossible to perform). For reference to MHAQ, it is 
referred to Material and methods chapter. 
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Paper IV: 
In the table text of Table 2, sum vitamin A should read sum retinol (13-, 11-, 9-cis and 
all-trans retinol, i.e. A1) and 3,4 didehydro-all-trans retinol (A2). 
Paper V:  
Correct institutional association of co-authors are NIFES; Department of Biomedicine, 
University of Bergen; Institute of Medicine, University of Bergen and Haukeland 
University Hospital.  
Figure 2: The correct version is given below. 
In addition to the above corrections, which were submitted when delivering the thesis 
for review, the following changes have been made before final printing: 
Page 3: The English version of the logo for Haukeland University Hospital is used. 
Page 9/Paper VI: a revised version (including contents, title and original errata) of the 
submitted manuscript is accepted for publication (in press, www.sciencedirect.com).  
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Page 13-14: The following abbreviations with explanation were introduced for  
clarity: ALA, CRP, DPA, ELISA, GLC, GMP, HUH, HPLC, LCITMS, LMF,  
LOQ, LOX, MHAQ, MUFA, NIFES, PASI, PGE2-d4, SF-36, SF-NDI, SpA, TAG,  
TBARS, TNF-α, UoB and w/w. Inconsistently used abbreviations are corrected  
throughout the thesis. 
Page 23: “Leukotriene (LTB4) is changed to ” leukotriene B4 (LTB4)”. 
Page 25: “43 %” is changed to “43 % (34 patients)” 
Page 29: Table 1; “n-3” is changed to “LC n-3 PUFA” with abbreviation explained in 
table text. Besides, “VO” in table text is clarified as “vegetable oil (soy oil)”.
Page 30: “WO” is changed to “WO (from adult minke whales)”. 
Page 35: “Vitamin D2“ is changed to “vitamin D2 (ergocalciferol) and “vitamin D3“ is  
changed to “vitamin D3 (cholecalciferol)”. 
Page 37: “ANOVA” is changed to “ANOVA (analysis of variance)”. 
Page 41: “EPIC” is changed to “EPIC (Epanova Program in Crohn's Study)”. 
Page 42: “25 (OH)D” is changed to “25-hydroxyvitamin D (25(OH)D)”. 
References: Due to a mishap with the reference system, some of the references have 
been corrected, notably number 50, 58, 63-65, 67, 69, 73, 75, 86, 88-90, 94, 97, 112 
and 114 (some of these references have been used in papers). 
A few linguistic and layout errors have been corrected throughout the thesis (resulting 
in no scientific changes): e.g. “prostaglandin E2” is changed to “prostaglandin E2”. 
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